SHIELD THERAPEUTICS PLC — AGM Information 2016

Jun 30, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8817C

Shield Therapeutics PLC

30 June 2016

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

2015 Annual Report and Accounts and AGM Notification

London, UK, 30 June 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical Company focused on secondary care, gives notice that copies of the 2015 Annual Report and Accounts have been sent to shareholders.  This document is available on the "Investors" section of the Company's website at www.shieldtherapeutics.com. Shield announced preliminary results for the year ended 31 December 2015 on 14 June 2016.

Further copies of the Annual Report will be available from the Company Secretary, Shield Therapeutics, Northern Design Centre, Gateshead Quays, NE8 3DF.

Shield also announces that its Annual General Meeting will be held on 4 August 2016. The meeting will be held at Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH, commencing at 10.00 am. Notice of the Annual General Meeting will be sent to shareholders by Monday 11th July 2016.

- Ends -

For further information please contact:

Shield Therapeutics plc	+44 (0)191 511 8507
Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer
NOMAD Liberum Capital Limited Christopher Britton/Steve Pearce	+44 (0)20 3100 2222
Financial PR Advisor Consilium Strategic Communications	+44 (0)203 709 5700 shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott/Matthew Neal/Lindsey Neville/Hendrik Thys

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need.  The Company has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA).  In addition, the Company has a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia), PT20. Shield, based in London and Newcastle, joined LSE's AIM in 2016 under the ticker STX. For more information please visit www.shieldtherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCWGUCUQUPQGQU